The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Circulating FGF21 proteolytic processing mediated by fibroblast activation protein
Open accessAbstract
Fibroblast growth factor 21 (FGF21), a hormone implicated in the regulation of glucose homoeostasis, insulin sensitivity, lipid metabolism and body weight, is considered to be a promising therapeutic target for the treatment of metabolic disorders. Despite observations that FGF21 is rapidly proteolysed in circulation rending it potentially inactive, little is known regarding mechanisms by which FGF21 protein levels are regulated. We systematically investigated human FGF21 protein processing using mass spectrometry. In agreement with previous reports, circulating human FGF21 was found to be cleaved primarily after three proline residues at positions 2, 4 and 171. The extent of FGF21 processing was quantified in a small cohort of healthy human volunteers. Relative abundance of FGF21 proteins cleaved after Pro-2, Pro-4 and Pro-171 ranged from 16 to 30%, 10 to 25% and 10 to 34%, respectively. Dipeptidyl peptidase IV (DPP-IV) was found to be the primary protease responsible for N-terminal cleavages after residues Pro-2 and Pro-4. Importantly, fibroblast activation protein (FAP) was implicated as the protease responsible for C-terminal cleavage after Pro-171, rendering the protein inactive. The requirement of FAP for FGF21 proteolysis at the C-terminus was independently demonstrated by in vitro digestion, immunodepletion of FAP in human plasma, administration of an FAP-specific inhibitor and by human FGF21 protein processing patterns in FAP knockout mouse plasma. The discovery that FAP is responsible for FGF21 inactivation extends the FGF21 signalling pathway and may enable novel approaches to augment FGF21 actions for therapeutic applications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Notably, human but not mouse FGF21 is cleaved and processed by FAP, because mouse FGF21 possesses a single–amino acid difference in the stringent FAP-recognition motif42,43.”
From Metabolic messengers: FGF21 (2021) · cites this paper as [43]
In the citing paper
“FGF21 is also subject to proteolytic cleavage by the serine proteases fibroblast activation protein (FAP) and dipeptidyl peptidase IV (DPP-IV)42,43.”
From Metabolic messengers: FGF21 (2021) · cites this paper as [43]
In the citing paper
“Circulating human FGF21 is composed of 181 amino acids and is proteolytically cleaved, and inactivated, between Pro-171 and Ser-172 by the endopeptidase fibroblast activation protein (FAP) (29, 150).”
From Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis (2018) · cites this paper as [150]
In the citing paper
“Interestingly, mouse FGF21 is neither cleaved nor inactivated by FAP because mouse FGF21 has a glutamate residue at the corresponding glycine residue at position 170, which disrupts the stringent glycine–proline sequence required for FAP-mediated cleavage (29, 150).”
From Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis (2018) · cites this paper as [150]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040
Ogurtsova, K., Fernandes, J. D. D. R., Huang, Y., Linnenkamp, U., Guariguata, L., Cho, N. H., Cavan, D. A., Shaw, J. E., & Makaroff, L. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.03.024 · Cited by 7,138
IDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030
Whiting, D. R., Guariguata, L., Weil, C., & Shaw, J. E. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.10.029 · Cited by 4,018
The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes
Gaich, G., Chien, J. Y., Fu, H., Glass, L. C., Deeg, M. A., Holland, W. L., Kharitonenkov, A., Bumol, T., Schilske, H. K., & Moller, D. E. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.08.005 · Cited by 885
The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21
Kharitonenkov, A., Wroblewski, V. J., Koester, A., Chen, Y.-F., Clutinger, C. K., Tigno, X. T., Hansen, B. C., Shanafelt, A. B., & Etgen, G. J. (2007) · Endocrinology · doi:10.1210/en.2006-1168 · Cited by 738
Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease
Itoh, N., & Ornitz, D. M. (2010) · The Journal of Biochemistry · doi:10.1093/jb/mvq121 · Cited by 726
Scanlan, M. J., Raj, B. K. M., Calvo, B. F., Garin‐Chesa, P., Sanz-Moncasi, M. P., Healey, J. H., Old, L. J., & Rettig, W. J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.12.5657 · Cited by 577
Gälman, C., Lundåsen, T., Kharitonenkov, A., Bina, H. A., Eriksson, M., Hafström, I., Dahlin, M., Åmark, P., Angelin, B., & Rudling, M. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.06.014 · Cited by 512
Biological actions and therapeutic potential of the glucagon-like peptides
Drucker, D. J. (2002) · Gastroenterology · doi:10.1053/gast.2002.31068 · Cited by 509
Hamson, E., Keane, F. M., Tholen, S., Schilling, O., & Gorrell, M. D. (2014) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201300095 · Cited by 501
Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice
Santos, A., Jung, J. J., Aziz, N., Kissil, J. L., & Puré, E. (2009) · Journal of Clinical Investigation · doi:10.1172/jci38988 · Cited by 436
Flagged first, then by citations
Cited by
Sorted by citations
The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic
Geng, L., Lam, K. S. L., & Xu, A. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0386-0 · Cited by 607
The role of fibroblast activation protein in health and malignancy
Fitzgerald, A. A., & Weiner, L. M. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09909-3 · Cited by 640
Pro-tumorigenic roles of fibroblast activation protein in cancer: back to the basics
Puré, E., & Blomberg, R. (2018) · Oncogene · doi:10.1038/s41388-018-0275-3 · Cited by 399
FGF21 as Modulator of Metabolism in Health and Disease
Tezze, C., Romanello, V., & Sandri, M. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00419 · Cited by 319
Flippo, K. H., & Potthoff, M. J. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00354-2 · Cited by 311
Fibroblast Growth Factor 21—Metabolic Role in Mice and Men
Staiger, H., Keuper, M., Berti, L., Hrabě de Angelis, M., & Häring, H.-U. (2017) · Endocrine Reviews · doi:10.1210/er.2017-00016 · Cited by 270
Structures of β-klotho reveal a ‘zip code’-like mechanism for endocrine FGF signalling
Lee, S., Choi, J., Mohanty, J., Sousa, L. P., Tome, F., Pardon, E., Steyaert, J., Lemmon, M. A., Lax, I., & Schlessinger, J. (2018) · Nature · doi:10.1038/nature25010 · Cited by 236
Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis
BonDurant, L. D., & Potthoff, M. J. (2018) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071816-064800 · Cited by 222
FGF21 Is a Sugar-Induced Hormone Associated with Sweet Intake and Preference in Humans
Søberg, S., Sandholt, C. H., Jespersen, N. Z., Toft, U., Madsen, A. L., von Holstein-Rathlou, S., Grevengoed, T. J., Christensen, K. B., Bredie, W. L. P., Potthoff, M. J., et al. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.04.009 · Cited by 216
Tillman, E. J., & Rolph, T. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.601290 · Cited by 214
Going Back to the Biology of FGF21: New Insights
Lewis, J. E., Ebling, F. J. P., Samms, R. J., & Tsintzas, K. (2019) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2019.05.007 · Cited by 170
Targeting fibroblast activation protein in cancer ndash Prospects and caveats
Šedo, A. (2018) · Frontiers in bioscience · doi:10.2741/4682 · Cited by 166
Fibroblast Activation Protein Cleaves and Inactivates Fibroblast Growth Factor 21
Dunshee, D. R., Bainbridge, T. W., Kljavin, N. M., Zavala-Solorio, J., Schroeder, A. C., Chan, R., Corpuz, R., Wong, M., Zhou, W., Deshmukh, G., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.710582 · Cited by 158
New developments in the biology of fibroblast growth factors
Ornitz, D. M., & Itoh, N. (2022) · WIREs Mechanisms of Disease · doi:10.1002/wsbm.1549 · Cited by 147
Stanislaus, S., Hecht, R. I., Yie, J., Hager, T., Hall, M. P., Spahr, C. S., Wang, W., Weiszmann, J., Li, Y., Deng, L., et al. (2017) · Endocrinology · doi:10.1210/en.2016-1917 · Cited by 114
Mitochondrial stress and mitokines in aging
Burtscher, J., Soltany, A., Visavadiya, N. P., Burtscher, M., Millet, G. P., Khoramipour, K., & Khamoui, A. V. (2023) · Aging Cell · doi:10.1111/acel.13770 · Cited by 123
Can Targeting Stroma Pave the Way to Enhanced Antitumor Immunity and Immunotherapy of Solid Tumors?
Puré, E., & Lo, A. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0011 · Cited by 112
FGF21-receptor agonists: an emerging therapeutic class for obesity-related diseases
Sonoda, J., Chen, M. Z., & Baruch, A. (2017) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2017-0002 · Cited by 110
Fibroblast growth factor 21 night watch: advances and uncertainties in the field
Kharitonenkov, A., & DiMarchi, R. D. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12580 · Cited by 97
Søberg, S., Andersen, E. S., Dalsgaard, N. B., Jarlhelt, I., Hansen, N. L., Hoffmann, N., Vilsbøll, T., Chenchar, A., Jensen, M., Grevengoed, T. J., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.03.010 · Cited by 94
Baruch, A., Wong, C., Chinn, L. W., Vaze, A., Sonoda, J., Gelzleichter, T., Chen, S., Lewin-Koh, N., Morrow, L., Dheerendra, S., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2012073117 · Cited by 95
Self-citationFibroblast Growth Factor 21 and the Adaptive Response to Nutritional Challenges
Martínez‐Garza, Ú., Torres‐Oteros, D., Yarritu, A., Marrero, P. F., Haro, D., & Relat, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194692 · Cited by 88
FGF19 and FGF21: In NASH we trust
Talukdar, S., & Kharitonenkov, A. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101152 · Cited by 82
Circulating FGF21 Levels in Human Health and Metabolic Disease
Keuper, M., Häring, H., & Staiger, H. (2019) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-0879-2968 · Cited by 83
Fibroblast activation protein (FAP) as a novel metabolic target
Sanchez-Garrido, M. A., Habegger, K. M., Clemmensen, C., Holleman, C. L., Müller, T. D., Pérez–Tilve, D., Li, P., Agrawal, A., Finan, B., Drucker, D. J., et al. (2016) · Molecular Metabolism · doi:10.1016/j.molmet.2016.07.003 · Cited by 79
Molecular recognition of fibroblast activation protein for diagnostic and therapeutic applications
Šimková, A., Bušek, P., Šedo, A., & Konvalinka, J. (2020) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2020.140409 · Cited by 71
Human FGF-21 Is a Substrate of Fibroblast Activation Protein
Coppage, A. L., Heard, K. R., DiMare, M. T., Liu, Y., Wu, W., Lai, J. H.-S., & Bachovchin, W. W. (2016) · PLoS ONE · doi:10.1371/journal.pone.0151269 · Cited by 71
Phan, P., Saikia, B. B., Sonnaila, S., Agrawal, S., Alraawi, Z., Kumar, T. K. S., & Iyer, S. (2021) · Cells · doi:10.3390/cells10092418 · Cited by 70
Zhang, H. E., Hamson, E., Koczorowska, M. M., Tholen, S., Chowdhury, S., Bailey, C. G., Lay, A. J., Twigg, S. M., Lee, Q., Roediger, B., et al. (2018) · Molecular & Cellular Proteomics · doi:10.1074/mcp.ra118.001046 · Cited by 69
FGF21 Is an Insulin-Dependent Postprandial Hormone in Adult Humans
Samms, R. J., Lewis, J. E., Norton, L., Stephens, F. B., Gaffney, C. J., Butterfield, T., Smith, D. P., Cheng, C. C., Perfield, J. W., Adams, A. C., et al. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01257 · Cited by 65
Juillerat‐Jeanneret, L., Tafelmeyer, P., & Golshayan, D. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1370455 · Cited by 65
Basalova, N. A., Alexandrushkina, N. A., Grigorieva, O., Kulebyakina, M., & Efimenko, A. Y. (2023) · Biomolecules · doi:10.3390/biom13121718 · Cited by 56
Adipokines as Clinically Relevant Therapeutic Targets in Obesity
Würfel, M., Blüher, M., Stümvoll, M., Ebert, T., Kovacs, P. L., Tönjes, A., & Breitfeld, J. (2023) · Biomedicines · doi:10.3390/biomedicines11051427 · Cited by 56
Antifibrotic therapies for metabolic dysfunction-associated steatotic liver disease
Schwabe, R. F., Tacke, F., Sugimoto, A., & Friedman, S. L. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101421 · Cited by 52
Molecular elements in FGF19 and FGF21 defining KLB/FGFR activity and specificity
Agrawal, A., Parlee, S. D., Pérez–Tilve, D., Li, P., Pan, J. H., Mroz, P. A., Hansen, A. M. K., Andersen, B., Finan, B., Kharitonenkov, A., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.05.003 · Cited by 42
Recent Clinical Implications of FAPI
Kiani, M., Jokar, S., Hassanzadeh, L., Behnammanesh, H., Bavi, O., Beiki, D., & Assadi, M. (2024) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000005348 · Cited by 41
Selective Homogeneous Assay for Circulating Endopeptidase Fibroblast Activation Protein (FAP)
Bainbridge, T. W., Dunshee, D. R., Kljavin, N. M., Skelton, N. J., Sonoda, J., & Ernst, J. A. (2017) · Scientific Reports · doi:10.1038/s41598-017-12900-8 · Cited by 40
Mitochondrial Stress and Mitokines: Therapeutic Perspectives for the Treatment of Metabolic Diseases
Zhang, B., Chang, J. Y., Lee, M. H., Ju, S. H., Yi, H., & Shong, M. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2023.0115 · Cited by 39
Khalafi, M., Alamdari, K. A., Symonds, M. E., Nobari, H., & Carlos-Vivas, J. (2021) · HORMONES · doi:10.1007/s42000-020-00245-3 · Cited by 34
FAP expression in adipose tissue macrophages promotes obesity and metabolic inflammation
Wu, Y., Wu, C., Shi, T., Cai, Q., Wang, T., Xiong, Y., Zhang, Y., Jiang, W., Lu, M., Chen, Z., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2303075120 · Cited by 35
Hepatic FGF21: Its Emerging Role in Inter-Organ Crosstalk and Cancers
Sui, Y., & Chen, J. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.76924 · Cited by 33
Rosenstock, M., Tseng, L., Pierce, A. A., Offman, E., Chen, C.-Y., Charlton, R., Margalit, M., & Mansbach, H. (2023) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.123.001618 · Cited by 31
A systematic dissection of sequence elements determining β-Klotho and FGF interaction and signaling
Shi, S. Y., Lu, Y., Richardson, J., Min, X., Weiszmann, J., Richards, W. G., Wang, Z., Zhang, Z., Zhang, J., & Li, Y. (2018) · Scientific Reports · doi:10.1038/s41598-018-29396-5 · Cited by 31
Brennen, W. N., Thorek, D. L. J., Jiang, W., Krueger, T. E. G., Antony, L., Denmeade, S. R., & Isaacs, J. T. (2020) · Immunotherapy · doi:10.2217/imt-2020-0066 · Cited by 33
Zhang, Z., Tao, J., Qiu, J., Cao, Z., Huang, H., Xiao, J., & Zhang, T. (2023) · Cellular Oncology · doi:10.1007/s13402-023-00872-z · Cited by 31
Higher serum levels of fibroblast growth factor 21 in old patients with cachexia
Franz, K., Ost, M., Otten, L., Herpich, C., Coleman, V., Endres, A., Klaus, S., Müller‐Werdan, U., & Norman, K. (2018) · Nutrition · doi:10.1016/j.nut.2018.11.004 · Cited by 31
Fjeldborg, K., Pedersen, S. B., Møller, H. J., & Richelsen, B. (2017) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2017.03.033 · Cited by 28
Han, M., Pearson, J. T., Wang, Y., Winters, D., Soto, M., Rock, D. A., & Rock, B. M. (2017) · Analytical Biochemistry · doi:10.1016/j.ab.2017.10.005 · Cited by 28
Lin, D., Wallace, M. A., Allentoff, A. J., Donnelly, D. J., Gomes, E., Voronin, K., Gong, S. X., Huang, R. Y. ‐., Kim, H., Caceres‐Cortes, J., et al. (2020) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.0c00256 · Cited by 28
Shi, Y., Kong, Z., Liu, P., Hou, G., Wu, J., Ma, W., Cheng, X., & Wang, Y. (2021) · Cells · doi:10.3390/cells10051142 · Cited by 31
Dufresne, J., Bowden, P., Thavarajah, T., Florentinus-Mefailoski, A., Chen, Z. Z., Tucholska, M., Norzin, T., Ho, M. T., Phan, M., Mohamed, N., et al. (2018) · Clinical Proteomics · doi:10.1186/s12014-018-9211-3 · Cited by 28
Development of a long acting FGF21 analogue-albumin fusion protein and its anti-diabetic effects
Watanabe, H., Miyahisa, M., Chikamatsu, M., Nishida, K., Minayoshi, Y., Takano, M., Ichimizu, S., Kobashigawa, Y., Morioka, H., Maeda, H., et al. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.05.036 · Cited by 24
Endocrine Fibroblast Growth Factors in Relation to Stress Signaling
Shimizu, M., & Sato, R. (2022) · Cells · doi:10.3390/cells11030505 · Cited by 25
Cho, J. M., Yang, E. H., Quan, W., Nam, E. H., & Cheon, H. G. (2020) · Scientific Reports · doi:10.1038/s41598-020-77978-z · Cited by 24
Fibroblast growth factor 21: A “rheostat” for metabolic regulation?
She, Q.-Y., Bao, J., Wang, H.-Z., Liang, H., Huang, W., Wu, J., Zhong, Y.-W., Ling, H., Li, A., & Qin, S.-L. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155166 · Cited by 22
Panaro, B. L., Coppage, A. L., Beaudry, J. L., Varin, E. M., Kaur, K., Lai, J. H.-S., Wu, W., Liu, Y., Bachovchin, W. W., & Drucker, D. J. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.10.011 · Cited by 22
Tillman, E. J., Brock, W. J., & Rolph, T. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15725 · Cited by 22
Meal sugar-protein balance determines postprandial FGF21 response in humans
Ramne, S., Duizer, L., Nielsen, M. S., Jørgensen, N. R., Svenningsen, J. S., Grarup, N., Sjödin, A. M., Raben, A., & Gillum, M. P. (2023) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00241.2023 · Cited by 20
Ebrahimi, F., Wolffenbuttel, C., Blum, C. A., Baumgartner, C., Müeller, B., Schüetz, P., Meier, C., Kraenzlin, M., Christ‐Crain, M., & Betz, M. J. (2018) · European Respiratory Journal · doi:10.1183/13993003.00973-2018 · Cited by 19
Brooks, N. E., Hjortebjerg, R., Henry, B. E., List, E. O., Kopchick, J. J., & Berryman, D. E. (2016) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2016.08.003 · Cited by 18
Kaur, N., Gare, S. R., Ruiz‐Velasco, A., Miller, J. M., Abouleisa, R., Ou, Q., Shen, J., Soran, H., Mohamed, T., & Liu, W. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e14952 · Cited by 18
Parmar, B., Lewis, J. E., Samms, R. J., Ebling, F. J. P., Cheng, C., Adams, A. C., Mallinson, J. E., Cooper, S., Taylor, T., Ghasemi, R., et al. (2018) · Experimental Physiology · doi:10.1113/ep086669 · Cited by 19
Rodgers, M., Heineman, B. D., & Dushay, J. R. (2019) · Obesity Science & Practice · doi:10.1002/osp4.360 · Cited by 17
Choi, Y., Johnson, J. D., Lee, J.-J., Song, J., Matthews, M. D., Hellerstein, M. K., & McWherter, C. A. (2023) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00158.2023 · Cited by 17
Ahmed, T. A., Ahmed, S. M., Elkhenany, H. A., El-Desouky, M. A., Magdeldin, S., Osama, A., Anwar, A. M., Mohamed, I. K., Abdelgawad, M. E., Hanna, D. H., et al. (2024) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-03643-1 · Cited by 18
Blomberg, R., Beiting, D. P., Wabitsch, M., & Puré, E. (2019) · Matrix Biology · doi:10.1016/j.matbio.2019.07.007 · Cited by 16
The fibroblast activation protein alpha as a biomarker of pulmonary fibrosis
Lavis, P., Garabet, A., Cardozo, A. K., & Bondue, B. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1393778 · Cited by 19
Arlien-Søborg, M. C., Grøndahl, C., Bæk, A., Dal, J., Madsen, M. A., Høgild, M. L., Pedersen, S. B., Bjerre, M., & Jørgensen, J. O. L. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz033 · Cited by 15
Exploring endocrine FGFs - structures, functions and biomedical applications
Phan, P. (2024) · International Journal of Biochemistry and Molecular Biology · doi:10.62347/palk2137 · Cited by 16
FAP finds FGF21 easy to digest
Gillum, M. P., & Potthoff, M. J. (2016) · Biochemical Journal · doi:10.1042/bcj20160004 · Cited by 14
Fibroblast activation protein is dispensable in the anti-influenza immune response in mice
Tan, S., Chowdhury, S., Polak, N., Gorrell, M. D., & Weninger, W. (2017) · PLoS ONE · doi:10.1371/journal.pone.0171194 · Cited by 13
Increased plasma apoM levels impair triglyceride turnover in mice
Hajny, S., Borup, A., Elsøe, S., & Christoffersen, C. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2021.158969 · Cited by 13
Crudele, L., García‐Irigoyen, O., Cariello, M., Piglionica, M., Scialpi, N., Florio, M., Piazzolla, G., Suppressa, P., Sabbà, C., Gadaleta, R. M., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1159127 · Cited by 12
Wu, Y., Shi, T., Wang, J., & He, R. (2020) · Obesity · doi:10.1002/oby.23058 · Cited by 12
The Role and Application of Fibroblast Activating Protein
Zhang, X.-L., Wang, X., Qian, J., Yang, W.-J., Xu, H., Xu, X.-D., & Zhang, G. (2023) · Current Molecular Medicine · doi:10.2174/1566524023666230530095305 · Cited by 12
Gómez-Sámano, M. Á., Vargas-Abonce, V. P., Martínez‐Sánchez, F. D., Palacios-Báez, L., Vera-Zertuche, J. M., Navarro-Flores, M. F., Morales-García, M., Fonseca-Correa, J. I., Zuarth-Vázquez, J. M., Vega‐Vega, O., et al. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188211001160 · Cited by 11
Metformin Improves the Prerequisites for FGF21 Signaling in Patients With Type 2 Diabetes
Pedersen, A. K. N., Gormsen, L. C., Nielsen, S., Jessen, N., & Bjerre, M. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad583 · Cited by 10
Development of Zalfermin, a Long-Acting Proteolytically Stabilized FGF21 Analog
Sass‐Ørum, K., Tagmose, T. M., Olsen, J., Sjölander, A., Wahlund, P., Han, D., Vegge, A., Reedtz‐Runge, S., Wang, Z., Gao, X., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00391 · Cited by 11
Ramne, S., García‐Ureña, M., Gillum, M. P., Ängquist, L. H., Hansen, T., Merino, J., & Grarup, N. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.102049 · Cited by 11
Parsing the Potential Neuroendocrine Actions of FGF21 in Primates
Gillum, M. P. (2018) · Endocrinology · doi:10.1210/en.2018-00208 · Cited by 9
Identification of BR102910 as a selective fibroblast activation protein (FAP) inhibitor
Jung, H. J., Nam, E. H., Park, J. Y., Ghosh, P., & Kim, I. S. (2021) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2021.127846 · Cited by 10
Maghraby, N., El‐Noweihi, A. M., El-Melegy, N. T., Mostafa, N., Abbas, A. M., El-Deek, H. E. M., & Radwan, E. (2021) · Reproductive Sciences · doi:10.1007/s43032-021-00810-0 · Cited by 10
Samms, R. J., Cheng, C., Fourcaudot, M. J., Heikkinen, S., Khattab, A., Adams, J. M., Cersósimo, E., Triplitt, C. L., PUCKETT, C. L., Tsintzas, K., et al. (2022) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00050.2022 · Cited by 10
Jung, Y., Lee, K. W., Cho, J. H., Bae, D., Jeong, B.-G., Jung, Y.-J., Park, S., An, Y. J., Kim, K., Lee, G. S., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-27717-x · Cited by 11
Zhao, Y., Liu, G., Kwok, S., Jones, B. R., Liu, J., Marchisin, D., Joyce, P., Peterson, J. E., & Shen, J. X. (2017) · Bioanalysis · doi:10.4155/bio-2017-0208 · Cited by 10
Research progress on the role of FGF21 in insulin resistance
Zhang, H., Zhu, R., Sun, Q., & Du, L. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1619462 · Cited by 10
Optimization of Peptide Inhibitors of β-Klotho as Antagonists of Fibroblast Growth Factors 19 and 21
Pan, J. B., Parlee, S. D., Brunel, F. M., Li, P., Lu, W., Pérez–Tilve, D., Liu, F., Finan, B., Kharitonenkov, A., & DiMarchi, R. D. (2020) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00100 · Cited by 9
Roles of FGF21 and irisin in obesity-related diabetes and pancreatic diseases
Xie, T., & Leung, P. S. (2020) · Journal of Pancreatology · doi:10.1097/jp9.0000000000000039 · Cited by 7
Nielsen, M. S., Ritz, C., Chenchar, A., Bredie, W. L. P., Gillum, M. P., & Sjödin, A. M. (2021) · Nutrients · doi:10.3390/nu13113840 · Cited by 7
Fibroblast growth factor 21 ameliorates cholestatic liver injury via a hepatic FGFR4-JNK pathway
Zhou, C., Pan, X., Huang, L., Wu, T., Zhao, T., Qi, J., Wu, J., Mukondiwa, A. V., Tang, Y., Luo, Y., et al. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166870 · Cited by 7
F AP deficiency enhances thermogenesis and attenuates metabolic inflammation in diet‐induced obesity
Wu, Y., Li, Y., Sun, M., Yu, F., Liu, H., Xu, J., & Tang, X. (2023) · Obesity · doi:10.1002/oby.23955 · Cited by 5
Treating metabolic dysfunction‐associated steatohepatitis: The fat‐trimming FGF21 approach
Li, X., Rao, Z., Hu, W., Lu, W., & Luo, Y. (2024) · Obesity Reviews · doi:10.1111/obr.13861 · Cited by 6
Hou, H.-W., Bishop, C. A., Huckauf, J., Broer, I., Klaus, S., Nausch, H., & Buyel, J. F. (2022) · Frontiers in Plant Science · doi:10.3389/fpls.2022.998596 · Cited by 5
Song, L., Ye, H., Lv, Z., Liu, Y., Lu, Z., Chen, J., Pan, H., Cai, L., Chen, Y., Huang, S., et al. (2025) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2025.114650 · Cited by 5
Nielsen, M. S., Søberg, S., Schmidt, J. B., Chenchar, A., Sjödin, A. M., & Gillum, M. P. (2021) · PeerJ · doi:10.7717/peerj.11174 · Cited by 5
Bibliometric analysis of fibroblast growth factor 21 research over the period 2000 to 2021
She, Q.-Y., Li, L., Liu, M.-H., Tan, R.-Y., Zhong, Y.-W., Bao, J., & Xie, J.-D. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1011008 · Cited by 9
Pedersen, A. K. N., Hage, C., Jessen, N., Mellbin, L., & Bjerre, M. (2022) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2022.111738 · Cited by 4
Ebrahimi, F., Urwyler, S. A., Betz, M. J., Christ, E., Schüetz, P., Müeller, B., Donath, M. Y., & Christ‐Crain, M. (2021) · Scientific Reports · doi:10.1038/s41598-021-87207-w · Cited by 3
Weight regain after bariatric surgery: Promoters and potential predictors
Demerdash, H. M. (2021) · World Journal of Meta-Analysis · doi:10.13105/wjma.v9.i5.438 · Cited by 3
Gastric bypass surgery mimetic approaches
Boettcher, B. R. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.04.009 · Cited by 3
Metadata
- Authors
- Zhen, E. Y., Jin, Z., Ackermann, B. L., Thomas, M. K., & Gutierrez, J. A.
- Affiliations
- Tailored Therapeutics, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, U.S.A.
- Eli Lilly (United States) (US)
- ORCID
- Thomas, Melissa K.
- Venue
- Biochemical Journal
- Publisher
- Portland Press Ltd.
- Published
- 2016-02-24
- Volume
- 473
- Issue
- 5
- Pages
- 605-614
- ISSN
- 0264-6021 (ISSN-L)
- 1470-8728
- PMC
- PMC4764976
- OpenAlex
- W2292257555
- Cited by
- 123
- References
- 54
- Citations by year
- 2026: 6 · 2025: 7 · 2024: 11 · 2023: 16 · 2022: 9 · 2021: 17 · 2020: 16 · 2019: 7 · 2018: 15 · 2017: 12 · 2016: 7
- FWCI
- 4.92
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Biochemical Journal (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- University of Pennsylvania
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fibroblast Growth Factor Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Peptidase Inhibition and Analysis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Connective Tissue Growth Factor Research
- Keywords
- FGF21, fibroblast activation protein, proteolytic processing, proteolytic cleavage, dipeptidyl peptidase IV, FAP inhibitors, metabolic disorders, glucose homeostasis, insulin sensitivity, lipid metabolism
- MeSH terms
- Animals, Fibroblasts, Humans, Insulin Resistance, Protein Processing, Post-Translational, Lipid Metabolism, Proteolysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
